US 10501538
Anti-LILRB antibodies and their use in detecting and treating cancer
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 10501538 (Anti-LILRB antibodies and their use in detecting and treating cancer) held by The Board of Regents of the University of Texas System expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P